<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Rep</journal-id><journal-id journal-id-type="publisher-id">IDR</journal-id><journal-title-group><journal-title>Infectious Disease Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7430</issn><issn pub-type="epub">2036-7449</issn><publisher><publisher-name>PAGEPress Publications, Pavia, Italy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7097833</article-id><article-id pub-id-type="pmid">32218915</article-id><article-id pub-id-type="doi">10.4081/idr.2020.8543</article-id><article-categories><subj-group subj-group-type="heading"><subject>Expert Opinion</subject></subj-group></article-categories><title-group><article-title>National Institute for the Infectious Diseases &#x0201c;L.
Spallanzani&#x0201d;, IRCCS. Recommendations for COVID-19 clinical
management</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nicastri</surname><given-names>Emanuele</given-names></name></contrib><contrib contrib-type="author"><name><surname>Petrosillo</surname><given-names>Nicola</given-names></name><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>Ascoli Bartoli</surname><given-names>Tommaso</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lepore</surname><given-names>Luciana</given-names></name></contrib><contrib contrib-type="author"><name><surname>Mondi</surname><given-names>Annalisa</given-names></name></contrib><contrib contrib-type="author"><name><surname>Palmieri</surname><given-names>Fabrizio</given-names></name></contrib><contrib contrib-type="author"><name><surname>D&#x02019;Offizi</surname><given-names>Gianpiero</given-names></name></contrib><contrib contrib-type="author"><name><surname>Marchioni</surname><given-names>Luisa</given-names></name></contrib><contrib contrib-type="author"><name><surname>Murachelli</surname><given-names>Silvia</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ippolito</surname><given-names>Giuseppe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Antinori</surname><given-names>Andrea</given-names><suffix>for the INMI COVID-19 Treatment Group (ICOTREG)</suffix></name><xref ref-type="aff" rid="aff001">*</xref></contrib></contrib-group><aff id="aff001"><institution>National Institute for Infectious Diseases &#x0201c;L.
Spallanzani&#x0201d;</institution>, <addr-line>IRCCS, Rome, Italy</addr-line></aff><author-notes><corresp id="cor1">National Institute for Infectious Diseases &#x0201c;L.
Spallanzani&#x0201d;, IRCCS, Via Portuense 292, 00149 Rome, Italy. <phone>+39</phone>
0655170432 - <fax>+39</fax> 0655170486. <email>nicola.petrosillo@inmi.it</email></corresp><fn fn-type="COI-statement"><p>Conflict of interest: The authors declare no potential conflict of interest.</p></fn></author-notes><pub-date pub-type="epub"><day>16</day><month>3</month><year>2020</year></pub-date><pub-date pub-type="collection"><day>25</day><month>2</month><year>2020</year></pub-date><volume>12</volume><issue>1</issue><elocation-id>8543</elocation-id><history><date date-type="received"><day>16</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>16</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9;Copyright: the Author(s), 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Licensee PAGEPress, Italy</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License (<uri xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</uri>) which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original
work is properly cited.</license-p></license></permissions><abstract><p>On January 9 2020, the World Health Organization (WHO) declared the identification, by
Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2
responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory
involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second
most affected country by COVID-19 infection after China. The &#x0201c;<italic>L.
Spallanzani</italic>&#x0201d; National Institute for the Infectious Diseases, IRCCS,
Rome, Italy, has been the first Italian hospital to admit and manage patients affected by
COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients,
based on very limited clinical evidences; they should be considered as expert opinions,
which may be modified according to newly produced literature data.</p></abstract><kwd-group><title>Key words</title><kwd>COVID-19</kwd><kwd>SARS-CoV-2</kwd><kwd>Treatment</kwd></kwd-group><counts><fig-count count="0"/><table-count count="0"/><equation-count count="0"/><ref-count count="44"/><page-count count="7"/></counts></article-meta></front><body><sec id="sec1-1"><title>Introduction</title><p>On January 9 2020, the World Health Organization (WHO) declared the identification, by
Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2. This
new virus, initially emerged in the Chinese city of Wuhan in December 2019, led to a sharply
spreading outbreak of human respiratory disease (COVID-2019), both within People&#x02019;s
Republic of China and in several other countries worldwide. On March 9 2020, WHO declared
COVID-19 a global pandemic. Currently, Italy is the second most affected country by COVID-19
infection after China. The first autochthonous infection case was confirmed in Italy on
February 21 <xref rid="ref3" ref-type="bibr">2020</xref> and up to now (March 12), 12462
cases with 827 deaths have been registered in Italy. Considering the recent evolution of
Italian epidemiologic picture, many health-care facilities will be likely in charge of
managing patients affected by COVID-19 in the next days. The &#x0201c;<italic>L.
Spallanzani</italic>&#x0201d; National Institute for the Infectious Diseases, IRCCS has
been the first Italian hospital to admit patients affected by COVID-19. Therefore, it will
be useful to share the protocol for the clinical management of COVID-19 confirmed cases,
applied within our Institute, in order to support other facilities that may have a limited
experience in treating COVID-19 patients.</p><p>Procedures described in the present document are applied in agreement with the
&#x0201c;Regional Network for the Infectious Diseases&#x0201d;, the &#x0201c;Regional Hospital
and Medical Specialties Network&#x0201d; and with the active cooperation of the
&#x0201c;Regional Agency for the Health Emergencies &#x02013; ARES 118&#x0201d;. This latter is
in charge for the response to the territorial health emergencies and for the transport of
patients within the hospital network. Recommendations described within this document are
based on very limited clinical evidences. Consequently, they should be considered as expert
opinions, which may be modified according to newly produced literature data.</p></sec><sec id="sec1-2"><title>COVID-19 case definition</title><sec id="sec2-1"><title>Suspected case</title><p><bold>a</bold>. A person with an acute respiratory infection (defined as acute onset of
at least one of the following sign/symptoms: fever, cough, respiratory difficulty
breathing)</p><p><bold>and</bold> without another etiology which completely explains the clinical
presentation</p><p><bold>and</bold> history of travels/stay in countries where there has been documented
local transmission* within the 14 days preceding symptoms onset</p><p><bold>OR</bold></p><p><bold>b</bold>. A person with an acute respiratory infection</p><p><bold>and</bold></p><p>history of close contact with a probable or confirmed COVID-19 case in the within the 14
days preceding symptoms onset</p><p><bold>OR</bold></p><p><bold>c.</bold> A person with a severe respiratory infection (fever and at least one
sign/symptom of respiratory disease <italic>e.g.</italic> cough or difficulty
breathing)</p><p><bold>and</bold></p><p>who require hospital admission</p><p><bold>and</bold></p><p>another etiology which completely explains the clinical presentation</p><p>In the setting of primary care/AE department in countries/areas where autochthonous
transmission has been observed, all patients with sings/symptoms of acute respiratory
infection should be considered as suspected cases.</p><p>*According to WHO reports available at: https://www.who.int/emergencies/diseases/
novel-coronavirus-2019/situationreports/</p></sec><sec id="sec2-2"><title>Probable case</title><p>A suspected case in which the result of SARS-COV-2 Real Time PCR performed at Regional
reference laboratories is doubtful or not conclusive or the result of a pan-coronavirus
test is positive.</p></sec><sec id="sec2-3"><title>Confirmed case</title><p>A person with laboratory confirmation of SARS-CoV-2 infection, performed at National
Reference Laboratory (&#x0201c;Istituto Superiore di Sanita&#x0201d;), irrespective of
clinical signs and symptoms.</p></sec></sec><sec id="sec1-3"><title>Clinical management based on case severity</title><sec id="sec2-4"><title>Asymptomatic or mild infection</title><p>Cases not presenting any clinical feature suggesting a complicated course of the
infection. Main goals of clinical management are:</p><list list-type="order"><list-item><p>Application of strict measures of infection prevention</p></list-item><list-item><p>Clinical monitoring, in order to early identify possible signs of clinical
worsening</p></list-item></list><p>The application of strict measures of infection prevention should be applied for all
patients with suspected or confirmed infection, regardless of clinical severity.</p><p><bold>Characteristics:</bold></p><list list-type="bullet"><list-item><p>No symptoms or mild upper respiratory tract manifestations; stable clinical
picture</p></list-item></list><p><bold>Minimal additional microbiologic diagnostics:</bold></p><list list-type="bullet"><list-item><p>Influenza virus detection and/or respiratory agents multiplex PCR on single
rhinopharyngeal swab sample</p></list-item><list-item><p>SARS-CoV-2 serology if available</p></list-item></list><p><bold>Clinical monitoring:</bold></p><list list-type="bullet"><list-item><p>Periodic clinical re-evaluation (once/work shift; thrice/day)</p></list-item><list-item><p>Periodic vital signs recording (blood pressure, heart rate, respiratory rate,
SpO<sub>2</sub>, GCS, body temperature) (once/work shift, thrice/day)</p></list-item></list><p><bold>Virologic monitoring:</bold></p><list list-type="bullet"><list-item><p>SARS-CoV-2 RT-PCR performed on rhinopharyngeal swab every 48-72 hours until
persistently negative</p></list-item></list><p><bold>Diagnostic imaging:</bold></p><list list-type="bullet"><list-item><p>Unnecessary</p></list-item><list-item><p>In case of cough and/or clinical examination suggesting possible lung Involvement,
perform chest X-ray</p></list-item></list><p><bold>Antiviral therapy:</bold></p><list list-type="bullet"><list-item><p>none</p></list-item></list><p><bold>Supportive therapy:</bold></p><list list-type="bullet"><list-item><p>Symptoms control</p></list-item></list></sec><sec id="sec2-5"><title>Stable patient presenting with respiratory and/or systemic symptoms
(<italic>e.g.</italic> MEWS clinical deterioration score &#x0003c;3)</title><p>Individuals presenting COVID-19 clinical symptoms or signs. Considering the burden of
clinical symptoms and the higher risk for complications, the goals of clinical management
are, in addition to the ones stated for the asymptomatic patients:</p><list list-type="order"><list-item><p>Closer monitoring of clinical conditions and analytical data</p></list-item><list-item><p>Strategy aimed at accelerating viral clearance, through use of potentially
efficacious experimental antiviral drugs</p></list-item></list><p><bold>Characteristics:</bold></p><list list-type="bullet"><list-item><p>Prostration, severe asthenia, high fever (&#x0003e;38&#x002da;C) and/or persistent cough, clinical or
radiological signs of lung involvement</p></list-item><list-item><p>No clinical or laboratoristic parameters of clinical severity and/or respiratory
impairment</p></list-item></list><p><bold>Additional microbiologic diagnostics:</bold></p><list list-type="bullet"><list-item><p>Influenza virus detection and/or respiratory agents multiplex PCR on single
rhinopharyngeal swab sample</p></list-item><list-item><p>SARS-CoV-2 serology if available</p></list-item><list-item><p>Urinary <italic>L. pneumophila</italic> and S. <italic>pneumoniae</italic> antigen
detection</p></list-item><list-item><p>In case of availability of samples representative of lower respiratory tract
(<italic>e.g.</italic> sputum), perform gram stain and culture; avoid
aerosol-generating procedures to induce sputum, because of the higher infectious risk
for healthcare workers</p></list-item><list-item><p>In case of fever (&#x0003e; 38&#x002da;C), perform at least 2 blood cultures, possibly before
starting new antimicrobial therapies</p></list-item></list><p><bold>Clinical monitoring:</bold></p><list list-type="bullet"><list-item><p>Periodic clinical re-evaluation (once/work shift; thrice/day)</p></list-item><list-item><p>Periodic vital signs recording (blood pressure, heart rate, respiratory rate,
SpO<sub>2</sub>, GCS, body temperature) (once/work shift, thrice/day), in order to
early identify a possible rapid worsening of respiratory functions requiring an
increase of the level of care</p></list-item><list-item><p>Arterial blood gas analysis monitoring (mainly between 5<sup>th</sup> and
7<sup>th</sup> day or if clinical worsening), to be evaluated together with the
intensive care specialist in charge</p></list-item></list><p><bold>Virologic monitoring:</bold></p><list list-type="bullet"><list-item><p>SARS-CoV-2 RT-PCR performed on rhinopharyngeal swab every 48-72 hours until
persistently negative</p></list-item></list><p><bold>Imaging diagnostics:</bold></p><list list-type="bullet"><list-item><p>Chest X-ray: useful as a first-line radiological examination, for the follow-up and
for a rapid assessment of certain pulmonary/thoracic emergencies. Quick and easy to
perform; in case of necessity, it can be performed using portable systems.</p></list-item><list-item><p>Chest computed tomography, without contrast: high sensitivity in identifying and
quantifying lung parenchymal involvement. No absolute indication at this stage of the
disease, but highly valuable, together with blood gas analysis, to predict clinical
worsening. Chest CT report should be evaluated together with the intensive care
specialist in charge</p></list-item></list><p><bold>Antiviral therapy:</bold></p><list list-type="simple"><list-item><p>- <bold>Lopinavir/ritonavir*</bold> 200/50 mg tablets, 2 tablets q12h, during 14 days
and</p><p><bold>Hydroxychloroquine phosphate **</bold>400 mg tablets, 1 tablet q12 as loading
dose, followed by 200 mg tablets, 1 tablet q12, during 10 days, or <bold>Chloroquine
phosphate**</bold> 250 mg tablets, 2 tablet q12, during 10 days</p></list-item><list-item><p>* Alternatively to Lopinavir/ritonavir, <bold>Darunavir</bold> 600 mg tablets, 1
tablet q12 plus <bold>Ritonavir</bold> 100 mg tablets, 1 tablet q12, during 14
days.</p></list-item><list-item><p>** Before chloroquine and hydrossichloroquine administration, G6PD deficiency test
should be performed.</p></list-item></list><p><bold>Supportive therapy:</bold></p><list list-type="bullet"><list-item><p>Symptomatic</p></list-item><list-item><p>Oral rehydration</p></list-item><list-item><p>Consider antimicrobial therapy (broad spectrum-empiric or based on microbiological
results)</p></list-item><list-item><p>Prompt availability of O<sub>2</sub>, in case of necessity</p></list-item></list></sec><sec id="sec2-6"><title>Patient affected by respiratory symptoms, clinically unstable, not in critical
conditions (<italic>e.g.</italic>: MEWS clinical deterioration score 3-4)</title><p>Patients presenting severe respiratory conditions related to SARS-CoV-2 infection and/or
to its complications. Adjunctive goals of clinical management at this stage are:</p><list list-type="order"><list-item><p>Strict monitoring, especially between 5<sup>th</sup> and 7<sup>th</sup> day since
symptoms onset, in order to ensure an immediate life support and an increase of the
level of care, whenever required</p></list-item><list-item><p>Maintenance of an adequate peripheral oxygenation, through O<sub>2</sub>
administration</p></list-item><list-item><p>Use of potentially efficacious antiviral experimental drugs, aimed at rapidly
reducing viral replication</p></list-item><list-item><p>Empirical or targeted treatment of possible bacterial co-infections;</p></list-item><list-item><p>Prompt assessment of the need of drugs aimed at modulating the immune and
inflammatory response, in order to counteract the evolution to ARDS</p></list-item></list><p><bold>Characteristics:</bold></p><list list-type="bullet"><list-item><p>Clinical and/or laboratoristic evidence of worsening of gas exchange (mild-tomoderate
dyspnoea, high respiratory rate, shortness of breath, low peripheral SpO<sub>2</sub>
or altered arterial blood gases while breathing room air), without any critical or
warning signs (severe respiratory failure, respiratory distress, consciousness
disorders, hypotension, shock)</p></list-item></list><p><bold>Additional microbiologic diagnostics:</bold></p><list list-type="bullet"><list-item><p>Influenza virus detection and/or respiratory agents multiplex PCR on single
rhinopharyngeal swab sample</p></list-item><list-item><p>SARS-CoV-2 serology if available</p></list-item><list-item><p>Urinary <italic>L. pneumophila</italic> and S. <italic>pneumoniae</italic> antigen
detection</p></list-item><list-item><p>In case of availability of sample representative of lower respiratory tract
(<italic>e.g.</italic> sputum), perform gram stain and culture; avoid
aerosol-generating procedures to induce sputum, because of the higher infectious risk
for healthcare workers</p></list-item><list-item><p>In case of fever (&#x0003e;38&#x002da;C), perform at least 2 blood cultures, possibly before starting
new antimicrobial therapies</p></list-item><list-item><p>Other eventual diagnostics based on the specific clinical picture
(<italic>e.g.</italic> HIV test, <italic>P. jirovecii</italic> detection on
respiratory fluids, MRSA on nasal swab, etc&#x02026;)</p></list-item></list><p><bold>Clinical monitoring:</bold></p><list list-type="bullet"><list-item><p>Strict clinical re-evaluation</p></list-item><list-item><p>Strict periodic vital signs recording (blood pressure, heart rate, respiratory rate,
SpO<sub>2</sub>, GCS, body temperature), in order to early identify a possible rapid
worsening of respiratory functions, requiring an increase of the level of care</p></list-item><list-item><p>Arterial blood gas analysis monitoring (mainly between 5<sup>th</sup> and
7<sup>th</sup> day), to be evaluated together with the intensive care specialist in
charge</p></list-item><list-item><p>Consultation with an intensive care specialist</p></list-item></list><p><bold>Virologic, immunologic and biochemical monitoring:</bold></p><list list-type="bullet"><list-item><p>SARS-CoV-2 RT-PCR performed on rhinopharyngeal swab every 48-72 hours until
persistently negative</p></list-item><list-item><p>IL-6 plasma levels</p></list-item><list-item><p>D-dimer, ferritin, fibrinogen, C-reactive protein, tryglicerides, lactate
dehydrogenase (LDH)</p></list-item></list><p><bold>Imaging diagnostics:</bold></p><list list-type="bullet"><list-item><p>Chest X-ray: useful as a first-line radiological examination, for the follow-up and
for a rapid assessment of certain pulmonary/thoracic emergencies. Quick and easy to
perform; in case of necessity, it can be performed using portable systems</p></list-item><list-item><p>Chest computed tomography, without contrast: high sensitivity in identifying and
quantifying lung parenchymal involvement. To be performed in every patient affected by
lung involvement causing respiratory failure. Use of contrast only in case of specific
clinical questions (<italic>e.g.</italic> pulmonary embolism). Chest CT report should
be evaluated together with the intensive care specialist in charge</p></list-item><list-item><p>Ecocardiography: indicated in case of suspected hearth failure as a contributing
factor to lung involvement/respiratory failure</p></list-item></list><p><bold>Antiviral therapy:</bold></p><list list-type="simple"><list-item><p>- <bold>Remdesivir</bold>&#x000b0; <bold>(GS-57324)</bold>, once daily
intravenously: 200 mg loading dose, followed by 100 mg daily maintenance dose, during
10 days, or (if Remdesivir not available)</p><p><bold>Lopinavir/ritonavir</bold>* 200/50 mg tablets, 2 tablets q12h, during 28 days
and</p><p><bold>Hydroxychloroquine phosphate **</bold>400 mg tablets, 1 tablet q12 as loading
dose, followed by 200 mg tablets, 1 tablet q12, during 10 days, or <bold>Chloroquine
phosphate**</bold> 250 mg tablets, 2 tablet q12, during 10 days and</p><p><bold>Tocilizumab</bold>^ 8 mg/kg (maximum 800 mg/dose), single dose intravenously
(1- hour infusion); in absence or with poor clinical improvement a second dose should
be administered after 8-12 hours</p></list-item><list-item><p>* Alternatively to Lopinavir/ritonavir, <bold>Darunavir</bold> 600 mg tablets, 1
tablet q12 plus <bold>Ritonavir</bold> 100 mg tablets, 1 tablet q12, during 14
days.</p></list-item><list-item><p>** Before chloroquine and hydroxychloroquine administration, G6PD deficiency test
should be performed</p></list-item><list-item><p>&#x000b0; Do not co-administrate Remdesivir with lopinavir/ritonavir, due to possible
drug interactions</p></list-item><list-item><p>^ Tocilizumab administration should be guided by the presence of 1 or more of
following selection criteria: a) PaO2/Fi02 ratio &#x0003c;300 mmHg; b) rapid worsening
of respiratory gas exchange with or without availability of non-invasive or invasive
ventilation; d) IL-6 levels &#x0003e;40 pg/mL (if not available, see Ddimer levels &#x0003e;1000
ng/mL.</p></list-item><list-item><p>Therapeutic schedule: 2 administrations (each 8 mg/kg, maximum 800 mg). Second
administration at 8-12 hours from the first one. Repeat PCR and Ddimer (+/-IL-6) after
24 hours from each administration.</p></list-item></list><p><bold>Supportive therapy:</bold></p><list list-type="bullet"><list-item><p>O<sub>2</sub> administration</p></list-item><list-item><p>Aantimicrobial therapy (broad spectrum- empiric or based on microbiological
results)</p></list-item><list-item><p>Oral or intravenous rehydration</p></list-item><list-item><p>Consider systemic steroids administration in case of clinical signs suggesting an
incipient worsening of respiratory functions (steroids are mandatory if Tocilizumab is
used) (methylprednisolone 1 mg/Kg daily intravenously for 5 days, followed by 40 mg
daily for 3 days and, lastly, 10 mg daily for 2 days, or dexamethasone 20 mg daily
intravenously for 5 days, followed by 10 mg daily for 3 days and lastly 5 mg daily for
2 days)</p></list-item></list></sec><sec id="sec2-7"><title>Critical patient <italic>(e.g.</italic> MEWS clinical deterioration score &#x0003e;4)</title><p>Patient affected by a very severe illness, due to severe respiratory failure or severe
impairment of other vital functions. Main goals during this stage are, in conjunction to
the procedures described for the unstable patient:</p><list list-type="order"><list-item><p>Life support and intensive monitoring</p></list-item><list-item><p>Rapid recognition and immediate management of complications</p></list-item><list-item><p>Active search for adjunctive or alternative diagnosis</p></list-item><list-item><p>Use of drugs aimed at reducing the impact of inflammatory response to ARDS</p></list-item></list><p><bold>Characteristics:</bold></p><list list-type="bullet"><list-item><p>Acute respiratory distress syndrome (ARDS)</p></list-item><list-item><p>Severe respiratory failure, respiratory distress</p></list-item><list-item><p>Hypotension - Shock</p></list-item><list-item><p>Multiorgan failure (MOF)</p></list-item><list-item><p>Consciousness impairment</p></list-item></list><p><bold>Additional microbiologic diagnostics:</bold></p><list list-type="bullet"><list-item><p>Influenza virus detection and/or respiratory agents multiplex PCR on single
rhinopharyngeal swab sample</p></list-item><list-item><p>SARS-CoV-2 serology if available</p></list-item><list-item><p>Urinary <italic>L. pneumophila</italic> and S. <italic>pneumoniae</italic> antigen
detection</p></list-item><list-item><p>In case of availability of samples representative of lower respiratory tract
(<italic>e.g.</italic>: sputum), perform gram stain and culture; avoid
aerosol-generating procedures to induce sputum, because of the higher infectious risk
for healthcare workers</p></list-item><list-item><p>In case of fever (&#x0003e; 38&#x002da;C), perform at least 2 blood cultures, possibly before
starting new antimicrobial therapies</p></list-item><list-item><p>Other eventual diagnostics based on the specific clinical picture
(<italic>e.g.</italic> HIV test, <italic>P. jirovecii</italic> detection on
respiratory fluids, MRSA on nasal swab, etc&#x02026;)</p></list-item></list><p><bold>Clinical monitoring:</bold></p><list list-type="bullet"><list-item><p>Strict monitoring and intensive care, starting from patients with moderate ARDS,
according to Berlin definition (100 mmHg&#x0003c;PaO<sub>2</sub>/FiO<sub>2</sub>&#x02264;200
mmHg)</p></list-item></list><p><bold>Virologic, immunologic and biochemical monitoring:</bold></p><list list-type="bullet"><list-item><p>SARS-CoV-2 RT-PCR performed on rhinopharyngeal swab every 48-72 hours until
persistently negative</p></list-item><list-item><p>SARS-CoV-2 RT-PCR performed on samples representing lower respiratory tract, using
the same timing</p></list-item><list-item><p>IL-6 plasma levels</p></list-item><list-item><p>D-dimer, ferritin, fibrinogen, C-reactive protein, tryglicerides, lactate
dehydrogenase (LDH)</p></list-item></list><p><bold>Imaging diagnostics:</bold></p><list list-type="bullet"><list-item><p>Chest computed tomography, without contrast: high sensitivity in identifying and
quantifying lung parenchymal involvement. To be performed in every patient affected by
lung involvement causing respiratory failure. Use of contrast only in case of specific
clinical questions (<italic>e.g.</italic> pulmonary embolism). The exam is required by
the intensive care specialist in charge</p></list-item><list-item><p>Ecocardiography: indicated in case of suspected hearth failure as a contributing
factor to lung involvement/respiratory failure</p></list-item></list><p><bold>Antiviral therapy:</bold></p><list list-type="simple"><list-item><p><bold>Remdesivir</bold>&#x000b0; <bold>(GS-57324)</bold>, once daily intravenously:
200 mg loading dose, followed by 100 mg daily maintenance dose, during 10 days, or (if
Remdesivir not available)</p><p><bold>Lopinavir/ritonavir</bold>* 200/50 mg tablets, 2 tablets q12h, during 14 days
and</p><p><bold>Hydroxychloroquine phosphate **</bold>400 mg tablets, 1 tablet q12 as loading
dose, followed by 200 mg tablets, 1 tablet q12, during 10 days, or</p><p><bold>Chloroquine phosphate**</bold> 250 mg tablets, 2 tablet q12, during 10 days
and</p><p><bold>Tocilizumab</bold>^ 8 mg/kg (maximum 800 mg/dose), single dose intravenously
(1- hour infusion); in absence or with poor clinical improvement a second dose should
be administered after 8-12 hours</p></list-item><list-item><p>* Alternatively to Lopinavir/ritonavir, <bold>Darunavir</bold> 600 mg tablets, 1
tablet q12 plus <bold>Ritonavir</bold> 100 mg tablets, 1 tablet q12, during 14
days.</p></list-item><list-item><p>** Before chloroquine and hydrossichloroquine administration, G6PD deficiency test
should be performed</p></list-item><list-item><p>&#x000b0; Do not co-administrate Remdesivir with lopinavir/ritonavir, due to possible
drug interactions</p></list-item><list-item><p>^ Tocilizumab administration should be guided by the following selection criteria: a)
PaO2/Fi02 ratio &#x0003c;300 mmHg; b) rapid worsening of respiratory gas exchange with
or without availability of non-invasive or invasive ventilation; d) IL-6 levels &#x0003e;40
pg/mL (if not available, see D-dimer levels &#x0003e;1000 ng/mL.</p></list-item></list><p><bold>Supportive therapy:</bold></p><list list-type="bullet"><list-item><p>Gold standard: early protective mechanical ventilation as recommended for patients
affected by ARDS sustainted by viral interstitial pneumonia</p></list-item><list-item><p>Antimicrobial therapy (broad spectrumempiric or based on microbiological results)</p></list-item><list-item><p>Intensive care and monitoring as indicated by hospital protocols</p></list-item><list-item><p>Systemic steroid therapy in case of ARDS/severe respiratory failure (steroids are
mandatory if Tocilizumab is used) (methylprednisolone 1 mg/Kg daily intravenously for
5 days, followed by 40 mg daily for 3 days and, lastly, 10 mg daily for 2 days, or
dexamethasone 20 mg daily intravenously for 5 days, followed by 10 mg daily for 3 days
and lastly 5 mg daily for 2 days)</p></list-item><list-item><p>Consider ECMO in case of refractory hypoxemia despite invasive mechanical
ventilation. Indication is given by the intensive care specialist in charge, according
to ECMONET criteria and to ECMO regional center</p></list-item></list></sec></sec><sec id="sec1-4"><title>ARDS criteria (Berlin definition &#x02013; 2012 + Kigali adaptation for low resource
settings)</title><p><bold>Onset:</bold> new or worsening respiratory symptoms within one week of known clinical
insult</p><p><bold>Chest imaging</bold> (radiograph, CT scan, or lung ultrasound): bilateral opacities,
not fully explained by effusions, lobar or lung collapse, or nodules</p><p><bold>Origin of oedema:</bold> respiratory failure not fully explained by cardiac failure
or fluid overload. Need objective assessment (<italic>e.g.</italic> echocardiography) to
exclude hydrostatic cause of oedema if no risk factor is present</p><p><bold>Oxygenation</bold> (adults):</p><list list-type="bullet"><list-item><p>Mild ARDS: 200 mmHg &#x0003c; PaO<sub>2</sub>/FiO<sub>2</sub> &#x02264; 300 mmHg (with PEEP or
CPAP &#x02265;5 cmH<sub>2</sub>O, or non-ventilated)</p></list-item><list-item><p>Moderate ARDS: 100 mmHg &#x0003c; PaO<sub>2</sub>/FiO<sub>2</sub> &#x02264;200 mmHg with PEEP &#x02265;5
cmH<sub>2</sub>O, or non-ventilated)</p></list-item><list-item><p>Severe ARDS: PaO<sub>2</sub>/FiO<sub>2</sub> &#x02264; 100 mmHg with PEEP &#x02265;5 cmH2O, or
non-ventilated)</p></list-item><list-item><p>When PaO<sub>2</sub> is not available, SpO<sub>2</sub>/FiO<sub>2</sub> &#x02264;315 suggests
ARDS (including in nonventilated patients)</p></list-item></list><p><bold>Oxygenation</bold> (children; note OI = Oxygenation Index and OSI = Oxygenation Index
using SpO<sub>2</sub>):</p><list list-type="bullet"><list-item><p>Bilevel NIV or CPAP &#x02265;5 cmH<sub>2</sub>O via full face mask:
PaO<sub>2</sub>/FiO<sub>2</sub> &#x02264; 300 mmHg or SpO<sub>2</sub>/FiO<sub>2</sub> &#x02264;264</p></list-item><list-item><p>Mild ARDS (invasively ventilated): 4 &#x02264; OI &#x0003c; 8 or 5 &#x02264; OSI &#x0003c; 7.5</p></list-item><list-item><p>Moderate ARDS (invasively ventilated): 8 &#x02264; OI &#x0003c; 16 or 7.5 &#x02264; OSI &#x0003c;
12.3</p></list-item><list-item><p>Severe ARDS (invasively ventilated): OI &#x02265; 16 or OSI &#x02265; 12.3</p></list-item></list></sec><sec id="sec1-5"><title>Antiviral/Immunological Therapy</title><p>There are currently no medications or vaccines proven to be effective for COVID- 19. Some
either old or new agents have been proposed and explored for treatment of COVID-19 but
clinical trials are still underway. Up to now, the only available data are based on
anecdotal experiences and expert opinions.</p><sec id="sec2-8"><title>Chloroquine and hydroxychloroquine</title><p>Chloroquine is an old and widely used anti-malarial drug and it is also efficacious as an
anti-inflammatory agent for rheumatologic disease. Earlier studies have demonstrated a
potential antiviral effect of this drug against SARS and avian influenza H5N1.</p><sec id="sec3-1"><title>Mechanism of Action</title><p>It has been postulated that antiviral action of chloroquine may depend by several
mechanisms such as the change of cell membrane pH which is necessary for viral fusion
and the interference with glycosylation of viral proteins. Hydroxychloroquine, an
analogue of chloroquine, has been proved to have similar if not better in-vitro efficacy
on SARS-Cov-2.</p></sec><sec id="sec3-2"><title>Available data on SARS-COV2</title><p>A recent study has demonstrated invitro efficacy of chloroquine and remdesivir in
inhibiting replication of SARS-COV2. Moreover, emerging reports from China suggests that
chloroquine has shown a superiority in reducing both the severity and the duration of
clinical disease without significant adverse events in almost one hundred patients. In
light of this results, an expert consensus group in China has recommended chloroquine
for COVID-19 treatment.</p></sec><sec id="sec3-3"><title>Dosage</title><p>The recommended dosage for SARSCoV- 2 infection is chloroquine 500 mg bid or
hydroxychloroquine 200 mg bid for 10 days in combination with another antiviral agent
(Lopinavir/ritonavir or Remdesivir).</p></sec><sec id="sec3-4"><title>Adverse Events/Cautions</title><p>Serious adverse effects may include: QT prolongation &#x00026; torsades de pointes,
reduction in seizure threshold, anaphylaxis or anaphylactoid reaction, neuromuscular
impairment, neuropsychiatric disorders (potential to increase delirium), pancytopenia,
neutropenia, thrombocytopenia, aplastic anemia, hepatitis.</p><p>Common adverse reactions: nausea/ vomiting, diarrhea, abdominal pain, visual
disturbance, headache, extrapyramidal symptoms</p><p>It is important to check G6PDH before starting treatment and during treatment to
monitor complete blood count, QT interval.</p><p>Contraindicated in: Porphyria, G6PD deficiency, epilepsy, heart failure, recent
myocardial infarction.</p></sec></sec><sec id="sec2-9"><title>Lopinavir/ritonavir</title><p>Lopinavir/ritonavir is a well-known protease inhibitor which has been widely used for
many years for the treatment of HIV infection. Compared to remdesivir, lopinavir/ritonavir
has the advantage that it&#x02019;s widely available and has an established toxicity and
drug-drug interactions profile. Its antiviral action against coronavirus infections has
been previously demonstrated both in-vitro and in-vivo (animal and human data) in studies
conducted on SARS (in combination with ribavirin) and MERS infection. Moreover, a
randomized clinical trial (RCTs) on lopinavir/ritonavir combined with IFNb use in MERS
infection is currently ongoing [MIRACLE Trial].</p><sec id="sec3-5"><title>Mechanism of Action</title><p>Lopinavir act its antiviral activity by inhibiting viral replication. As in HIV
infection, ritonavir only acts boosting lopinavir plasma levels.</p></sec><sec id="sec3-6"><title>Available data on SARS-COV2</title><p>Although only limited and anecdotal data are available of the clinical efficacy of
lopinavir/ritonavir in COVID-19 infection so far, it seems to rapidly reduce SARSCoV2
replication. Lopinavir/ritonavir is currently under investigation within several RCTs in
China.</p></sec><sec id="sec3-7"><title>Dosage</title><p>The recommended dose for COVID-19 is the 400/100 mg bid (the standard dose used for HIV
therapy). In case of swallowing difficulties or unconscious patient the oral solution of
lopinavir/ritonavir should be administrated (tablets cannot be crushed).</p></sec><sec id="sec3-8"><title>Adverse Events/Cautions</title><p>Serious adverse effects may include: Hypersensitivity reaction, angioedema,
Stevens-Johnson syndrome and Toxic epidermal necrolysis, EKG alterations (QT
prolongation &#x00026; Torsade de Pointes, AV block, PR prolongation), pancytopenia,
Pancreatitis, Hepatotoxicity</p><p>Common adverse reactions: gastrointestinal symptoms (nausea/vomiting, diarrhea)</p><p>Monitoring transaminase levels during treatment and drug-drug interactions before
treatment start.</p><p>In the light of the possible shortage of lopinavir/ritonavir stocks due to the
increasing prescriptions, we suggest the possible use of darunavir/ritonavir at the
dosage of 600 mg ever 12 hours in replacement of lopinavir/ritonavir considering the
similar mechanism of action and the optimal safety profile.</p></sec></sec><sec id="sec2-10"><title>Remdesivir (GS-5734)</title><p>Remdesivir is a novel nucleotide analogue currently under evaluation in clinical trials
for Ebola infection. Remdesevir has shown clinical an excellent activity against other
coronavirus infections (SARS, MERS) both in-vitro and in animal models.</p><sec id="sec3-9"><title>Mechanism of Action</title><p>It acts by inhibiting viral polymerase</p></sec><sec id="sec3-10"><title>Available data on SARS-COV2</title><p>A recent study exploring in-vitro activity of remdesivir and chloroquine has
demonstrated efficacy of the drugs in inhibiting replication of SARS-COV2. A recent case
report described the use of remdesivir, requested for compassionate use, in the first
patients with COVID-19 in the United States. Two ongoing clinical randomized clinical
trials in China are evaluating remdesivir for moderate and sever COVID-19
infections.</p><p><bold>To check drug-drug interactions of antiviral therapy please visit the University
of Liverpool website</bold>: <ext-link ext-link-type="uri" xlink:href="http://www.covid19-druginteractions.org">http://www.covid19-druginteractions.org</ext-link></p></sec></sec><sec id="sec2-11"><title>Tocilizumab</title><sec id="sec3-11"><title>Rationale for the use and mechanism of action</title><p>Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits
signal transduction by binding sIL- 6R and mIL-6R. The main approved indication is for
rheumatoid arthritis, in association or not with methotrexate.</p><p>In 2017, the U.S. Food and Drug Administration approved TCZ for the treatment of
cytokine release syndrome (CRS) consisting in a systemic inflammatory response caused by
the massive release of pro-inflammatory cytokines in response to iatrogenic
(<italic>e.g.</italic> CAR-t therapies) or infective stimuli.</p></sec><sec id="sec3-12"><title>Available data on SARS-COV2</title><p>Although the lack of data on SARSCoV- 2 pathogenesis, studies in China showed a
possible correlation of massive inflammation and severe lung damage on the rapid
evolution of fatal pneumonia.</p><p>Indeed, in COVID-19 patients, significant differences in IL-6 plasmatic levels were
observed at different stage of disease with a higher expression in severe cases than
mild ones. Moreover, in the biopsy samples at autopsy from a severe COVID- 19 patient,
histological examination showed diffuse alveolar damage with cellular fibromyxoid
exudates and interstitial mononuclear inflammatory infiltrates suggesting severe immune
injury.</p><p>Despite the lack of clinical trials on TCZ efficacy and safety for COVID-19 treatment,
in China TCZ was recently approved for patients affected by severe SARS-CoV-2 pulmonary
complications by the National Health Commission of the People&#x02019;s Republic of
China.</p><p>Preliminary data from an observational study conducted in China on 21 severe cases
receiving TCZ, showed an improvement of the clinical and radiological outcome.</p></sec><sec id="sec3-13"><title>Indications</title><p>TCZ is a potential treatment strategy in severe and critical COVID-19 patients. In
particular, patients who could benefit from TCZ therapy are:</p><list list-type="order"><list-item><p>Patients with respiratory symptoms, unstable and severe but not in critical
conditions (<italic>e.g.</italic> clinical instability score of MEWS 3-4) with
evidence of worsening of gas exchange with mild to moderate dyspnoea, tachypnea,
worsening of SpO2 or arterial blood gas analysis parameters in ambient air (SpO2 &#x02264;
93% in ambient air, PaO2/FiO2 &#x02264; 300 mmHg) in the absence of critical manifestations
or signs of alarm (severe respiratory failure, respiratory distress, altered state
of consciousness, hypotension, cardiovascular shock);</p></list-item><list-item><p>Patient with respiratory symptoms in critical conditions (<italic>e.g.</italic>
clinical instability score of MEWS &#x0003e; 4) with evidence of ARDS (from moderate ARDS
according to the Berlin definition: 100 mmHg &#x0003c;PaO2 / FiO2&#x02264;200 mmHg) or severe
respiratory failure or evidence of rapid worsening as respiratory distress with the
need for mechanical ventilation or the presence of shock or the presence of
concomitant organ failure with the need for intensive care monitoring.</p></list-item></list></sec><sec id="sec3-14"><title>Dosage</title><p>Although the optimal dose and schedule of TCZ for treatment of CRS is not known, the
intended posology is 8 mg/kg intravenously (maximum 800 mg/dose) infused over an hour.
Additional administration(s) are evaluated on the basis of patient&#x02019;s response to
TCZ 8-12 hours apart, in case of:</p><list list-type="bullet"><list-item><p>Absence/poor clinical improvement or clinical worsening and/or</p></list-item><list-item><p>Failure in reduction of 50% baseline Creactive protein (a reliable surrogate marker
of IL-6) or failure in normalization and/or</p></list-item><list-item><p>Failure in reduction in D-dimer, fibrinogen or ferritin levels.</p></list-item></list><p>Dosage adjustment is required in relation to blood parameters of liver function and
blood count according to the indications specified in the patient package insert.</p><p>It is advisable monitoring of the following blood parameters (full blood count
including platelet count, ALT/AST, LDH, fibrinogen, D-dimer, ferritin, C-reactive
protein and IL-6) at different time points: immediately before 1<sup>st</sup> infusion,
immediately before 2<sup>nd</sup> infusion, 24h after 2<sup>nd</sup> infusion, 36h after
2<sup>nd</sup> infusion.</p></sec><sec id="sec3-15"><title>Adverse events/cautions</title><p>Severe life-threatening infections and alterations in blood parameters as ALT / AST &#x0003e;5
ULN, absolute neutrophils count &#x0003c;500 cell/mmc and platelet count &#x0003c;50000
cell/mmc are contraindications for TCZ treatment. Caution is required in special
categories: pregnancy/breastfeeding, active /latent pulmonary tuberculosis,
bacterial/fungal infections, immune-related rheumatic disease or concomitant therapy
with anti-rejection drugs or immunomodulating therapies, hepatopaties (including viral
hepatitis). The safety profile of TCZ is well known. In the TQT study, the most common
marked laboratory abnormality was low neutrophil counts. Decreases were observed in mean
neutrophil counts following single doses of TCZ over the first 2 days post-treatment,
reaching a maximum at approximately 24 hours after the infusion. The observed incidence
of marked decreases in neutrophil counts increased with the higher dose of TCZ.
Thrombocytopenia and increase of liver function tests have also been described.</p><p>For more detailed information, the reader should refer to the patient package
insert.</p></sec></sec><sec id="sec2-12"><title>*INMI COVID-19 Treatment Group &#x02013; ICOTREG</title><p>Abdeddaim A, Agrati C, Albarello F, Antinori A, Ascoli Bartoli T, Baldini F,
Bellagamba R, Bevilacqua N, Bibas M, Biava G, Boumis E, Busso D, Camici M, Capobianchi
MR, Capone A, Caravella I, Cataldo A, Cerilli S, Chinello G, Cicalini S, Corpolongo A,
Cristofaro M, D&#x02019;Abramo A, Dantimi C, De Angelis G, De Palo MG, D&#x02019;Offizi G,
De Zottis F, Di Lorenzo R, Di Stefano F, Fusetti M, Galati V, Gagliardini R, Garotto G,
Gebremeskel Tekle Saba, Giancola ML, Giansante F, Girardi E, Goletti D, Granata G, Greci
MC, Grilli E, Grisetti S, Gualano G, Iacomi F, Iannicelli G, Ippolito G, Lepore L,
Libertone R, Lionetti R, Liuzzi G, Loiacono L, Macchione M, Marchioni L, Mariano A,
Marini MC, Maritti M, Mastrobattista A, Mazzotta V, Mencarini P, Migliorisi- Ramazzini
P, Mondi A, Montalbano M, Mosti S, Murachelli S, Musso M, Nicastri E, Noto P, Oliva A,
Palazzolo C, Palmieri F, Pareo C, Petrone A, Pianura E, Pinnetti C, Pontarelli A, Puro
V, Rianda A, Rosati S, Sampaolesi A, Santagata C, Scarcia D&#x02019;Aprano S, Scarabello
A, Schinin&#x000e0; V, Scorzolini L, Stazi GV, Taibi C, Taglietti F, Tonnarini R, Topino
S, Vergori A, Vincenzi L, Visco-Comandini U, Vittozzi P, Zaccarelli M, Zaccaro
G.</p></sec></sec></body><back><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal"><collab>European Centre for Disease Prevention
and Control</collab>. <article-title>Rapid Risk Assessment: Novel coronavirus disease
2019 (COVID-2019) pandemic: increased transmission in the EU/EEA &#x02013; sixth
update</article-title>. <source>ECDC: Stockholm;</source>. <year>2020</year>,
<comment>12 March 2020</comment> Available at: <comment><ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/sites/default/files/documents/RRA-sixth-update-Outbreak-of-novel-coronavirus-disease-2019-COVID-19.pdf">https://www.ecdc.europa.eu/sites/default/files/documents/RRA-sixth-update-Outbreak-of-novel-coronavirus-disease-2019-COVID-19.pdf</ext-link></comment></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal"><collab>Ministero della Salute</collab>.
<article-title>Direzione Generale della Prevenzione Sanitaria. Ufficio 5: Prevenzione
delle Malattie Trasmissibili e Profilassi Internazionale. Aggiornamento Circolare
09.03.2020. Allegato 1</article-title>. <source>Definizione di caso di COVID-19 per la
segnalazione</source>. Available at <comment><ext-link ext-link-type="uri" xlink:href="http://www.salute.gov.it/portale/documentazione/p6_2_6.jsp?lingua=italiano&#x00026;area=27&#x00026;btnCerca=cerca">http://www.salute.gov.it/portale/documentazione/p6_2_6.jsp?lingua=italiano&#x00026;area=27&#x00026;btnCerca=cerca</ext-link></comment>,
visited on March 13 <year>2020</year>.</mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal"><collab>WHO</collab>. <article-title>Global
Surveillance for human infection with coronavirus disease (COVID-2019)</article-title>.
<source>Revised guidance, 27 February</source>
<year>2020</year> Available at <comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications-detail/global-surveillance-for-human-infectionwith-novel-coronavirus-(2019-ncov)">https://www.who.int/publications-detail/global-surveillance-for-human-infectionwith-novel-coronavirus-(2019-ncov)</ext-link></comment>,
visited on 28 February <year>2020</year>.</mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal"><collab>European Centre for Disease Prevention
and Control</collab>. <article-title>An agency of the European Union</article-title>.
<source>Case definition for EU surveillance of COVID-19, as of 25 February</source>
<year>2020</year> Available at <comment><ext-link ext-link-type="uri" xlink:href="https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infectionnovel-coronavirus-2019-ncov">https://www.ecdc.europa.eu/en/case-definition-and-european-surveillance-human-infectionnovel-coronavirus-2019-ncov</ext-link></comment>,
visited on 28 February <year>2020</year>.</mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal"><collab>Centers for Disease Control and
Prevention (CDC)</collab>. <article-title>Interim Infection Prevention and Control
Recommendations for Patients with Confirmed Coronavirus Disease 2019 (COVID-19) or
Persons Under Investigation for COVID-19 in Healthcare Settings</article-title>.
<source>Updated February 21</source>, <year>2020</year> Available at <comment><ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/infectioncontrol/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html">https://www.cdc.gov/coronavirus/2019-ncov/infectioncontrol/control-recommendations.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fhcp%2Finfection-control.html</ext-link></comment>,
visited on February 28 <year>2020</year>.</mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Clinical characteristics and therapeutic
procedure for four cases with 2019 novel coronavirus pneumonia receiving combined
Chinese and Western medicine treatment</article-title>. <source>Biosci Trends 2020 Feb
9</source>. doi: 10.5582/bst.2020.01030.</mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>H</given-names></name></person-group>
<article-title>Drug treatment options for the 2019- new
coronavirus (2019-nCoV)</article-title>. <source>Biosci Trends 2020 Jan 28</source>.
doi:10.5582/bst.2020.01020.</mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group>
<article-title>Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China</article-title>. <source>Lancet</source>
<year>2020</year>;<volume>395</volume>:<fpage>497</fpage>-<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><etal/></person-group>
<article-title>Role of lopinavir/ritonavir in the
treatment of SARS: initial virological and clinical findings</article-title>.
<source>Thorax</source>
<year>2004</year>;<volume>59</volume>:<fpage>252</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momattin</surname><given-names>H</given-names></name><name><surname>Mohammed</surname><given-names>K</given-names></name><name><surname>Zumla</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Therapeutic options for Middle East
respiratory syndrome coronavirus (MERS-CoV)&#x02014;possible lessons from a systematic
review of SARS-CoV therapy</article-title>. <source>Int J Infect Dis</source>
<year>2013</year>;<volume>17</volume>:<fpage>e792</fpage>-<lpage>8</lpage>.<pub-id pub-id-type="pmid">23993766</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Momattin</surname><given-names>H</given-names></name><name><surname>Al-Ali</surname><given-names>AY</given-names></name><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name></person-group>
<article-title>A Systematic Review of therapeutic agents for the
treatment of the Middle East Respiratory Syndrome Coronavirus
(MERS-CoV)</article-title>. <source>Travel Med Infect Dis</source>
<year>2019</year>;<volume>30</volume>:<fpage>9</fpage>-<lpage>18</lpage>..<pub-id pub-id-type="pmid">31252170</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Remdesivir and chloroquine effectively
inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>.
<source>Cell Res 2020 Feb 4</source>. doi: 10.1038/s41422-020-0282-0.</mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>First Case of 2019 Novel Coronavirus in
the United States</article-title>. <source>N Engl J Med</source>
<year>2020</year> Jan 31. doi: 10.1056/NEJMoa2001191.</mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><etal/></person-group>
<article-title>Comparative therapeutic efficacy of
remdesivir and combination lopinavir, ritonavir, and interferon beta against
MERS-CoV</article-title>. <source>Nat Commun</source>
<year>2020</year>;<volume>11</volume>: <fpage>222</fpage>.<pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>CC</given-names></name><name><surname>Shih</surname><given-names>TP</given-names></name><name><surname>Ko</surname><given-names>WC</given-names></name><etal/></person-group>
<article-title>Severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) and coronavirus disease- 2019 (COVID-19): The epidemic and
the challenges</article-title>. <source>Int J Antimicrob Agents</source>
<year>2020</year>:<fpage>105924</fpage>. doi:
10.1016/j.ijantimicag.2020.105924.<pub-id pub-id-type="pmid">32081636</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal"><collab>NIH National Institutes of
Health</collab>. <article-title>NIH clinical trial of remdesivir to treat COVID-19
begins</article-title>. <source>Study enrolling hospitalized adults with COVID-19 in
Nebraska</source>. Tuesday, February 25, <year>2020</year> Available at
<comment><ext-link ext-link-type="uri" xlink:href="https://www.nih.gov/newsevents/news-releases/nih-clinical-trialremdesivir-treat-covid-19-begins">https://www.nih.gov/newsevents/news-releases/nih-clinical-trialremdesivir-treat-covid-19-begins</ext-link></comment>,
visited on February 28 <year>2020</year>.</mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>JP</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>RH</given-names></name><etal/></person-group>
<article-title>Expert consensus on the use of
corticosteroid in patients with 2019-nCoV pneumonia</article-title>. <source>Zhonghua
Jie He He Hu Xi Za Zhi</source>.
<year>2020</year>;<volume>43</volume>:<fpage>E007</fpage>.<pub-id pub-id-type="pmid">32034899</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal"><collab>ARDS Definition Task Force</collab>.
<article-title>Acute respiratory distress syndrome: the Berlin
Definition</article-title>. <source>JAMA</source>
<year>2012</year>;<volume>307</volume>:<fpage>2526</fpage>-<lpage>33</lpage>.<pub-id pub-id-type="pmid">22797452</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riviello</surname><given-names>ED</given-names></name><name><surname>Kiviri</surname><given-names>W</given-names></name><name><surname>Twagirumugabe</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Hospital Incidence and Outcomes of the
Acute Respiratory Distress Syndrome Using the Kigali Modification of the Berlin
Definition</article-title>. <source>Am J Respir Crit Care Med</source>
<year>2016</year>;<volume>193</volume>:
<fpage>52</fpage>-<lpage>9</lpage>.<pub-id pub-id-type="pmid">26352116</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khemani</surname><given-names>RG</given-names></name><name><surname>Smith</surname><given-names>LS</given-names></name><name><surname>Zimmerman</surname><given-names>JJ</given-names></name><etal/></person-group>
<article-title>Pediatric acute respiratory distress
syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute
Lung Injury Consensus Conference</article-title>. <source>Pediatr Crit Care Med</source>
<year>2015</year>;<volume>16</volume>:<fpage>S23</fpage>-<lpage>40</lpage>.<pub-id pub-id-type="pmid">26035358</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>MJ</given-names></name><name><surname>Bergeron</surname><given-names>E</given-names></name><name><surname>Benjannet</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Chloroquine is a potent inhibitor of SARS
coronavirus infection and spread</article-title>. <source>J Virol</source>
<year>2005</year>;<volume>2</volume>:<fpage>69</fpage>.</mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Anti-malaria drug chloroquine is highly
effective in treating avian influenza A H5N1 virus infection in an animal
model</article-title>. <source>Cell Res</source>
<year>2013</year>;<volume>23</volume>:<fpage>300</fpage>-<lpage>2</lpage>.<pub-id pub-id-type="pmid">23208422</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Remdesivir and chloroquine effectively
inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>.
<source>Cell Res</source>. <year>2020</year>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>In Vitro Antiviral Activity and Projection
of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute
Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)</article-title>. <source>Clin Infect
Dis</source>
<year>2020</year> Mar 9.</mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group>
<article-title>Breakthrough: Chloroquine phosphate has shown apparent efficacy in
treatment of COVID-19 associated pneumonia in clinical studies</article-title>.
<source>Biosci Trends</source>
<year>2020</year> Feb 19. doi: 0.5582/bst.2020.01047. [Epub ahead of
print]</mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal"><collab>Multicenter collaboration group of
Department of Science and Technology of Guangdong Province and Health Commission of
Guangdong Province for chloroquine in the treatment of novel coronavirus
pneumonia</collab>. <article-title>[Expert consensus on chloroquine phosphate for the
treatment of novel coronavirus pneumonia]</article-title>. <source>Zhonghua Jie He He Hu
Xi Za Zhi</source>. <year>2020</year> Feb
20;<volume>43</volume>:<fpage>E019</fpage>.<pub-id pub-id-type="pmid">32075365</pub-id></mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>CM</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><etal/></person-group>
<article-title>Role of lopinavir/ritonavir in the
treatment of SARS: initial virological and clinical findings</article-title>.
<source>Thorax</source>
<year>2004</year>;<volume>59</volume>:<fpage>252</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Lai</surname><given-names>ST</given-names></name><name><surname>Chu</surname><given-names>CM</given-names></name><etal/></person-group>
<article-title>Treatment of severe acute respiratory
syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort
study</article-title>. <source>Hong Kong Med J</source>
<year>2003</year>;<volume>9</volume>:<fpage>399</fpage>-<lpage>406</lpage>.<pub-id pub-id-type="pmid">14660806</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>JF</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Yeung</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Treatment With Lopinavir/Ritonavir or
Interferon- &#x003b2;1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of
Common Marmoset</article-title>. <source>J Infect Dis</source>
<year>2015</year>;<volume>212</volume>:<fpage>1904</fpage>-<lpage>13</lpage>.<pub-id pub-id-type="pmid">26198719</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>W</given-names></name><name><surname>Quan</surname><given-names>B</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>The course of clinical diagnosis and
treatment of a case infected with coronavirus disease 2019</article-title>. <source>J
Med Virol</source>
<year>2020</year> Feb 19.</mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>J</given-names></name><name><surname>Jeon</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>HY</given-names></name><etal/></person-group>
<article-title>Case of the Index Patient Who Caused
Tertiary Transmission of COVID-19 Infection in Korea: the Application of
Lopinavir/Ritonavir for the treatment of COVID-19 Infected Pneumonia Monitored by
Quantitative RT-PCR</article-title>. <source>J Korean Med Sci</source>
<year>2020</year>;<volume>35</volume>:<fpage>e79</fpage><pub-id pub-id-type="pmid">32056407</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Leist</surname><given-names>SR</given-names></name><etal/></person-group>
<article-title>Comparative therapeutic efficacy of
remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS
CoV</article-title>. <source>Nat Commun</source>
<year>2020</year>;<volume>11</volume>: <fpage>222</fpage>.<pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Cronin</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Prophylactic and therapeutic remdesivir
(GS-5734) treatment in the rhesus macaque model of MERS-CoV infection</article-title>.
<source>Proc Natl Acad Sci USA</source>
<year>2020</year> Feb 13.<volume>pii</volume>:<fpage>201922083</fpage></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostini</surname><given-names>ML</given-names></name><name><surname>Andres</surname><given-names>EL</given-names></name><name><surname>Sims</surname><given-names>AC</given-names></name><name><surname>Graham</surname><given-names>RL</given-names></name><name><surname>Sheahan</surname><given-names>TP</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Smith</surname><given-names>EC</given-names></name><etal/></person-group>
<article-title>Coronavirus susceptibility to the
antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading
exoribonuclease</article-title>. <source>mBio</source>
<year>2018</year>;<volume>9</volume>:<fpage>e00221</fpage>-<lpage>18</lpage>.<pub-id pub-id-type="pmid">29511076</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>First Case of 2019 Novel Coronavirus in
the United States</article-title>. <source>N Engl J Med</source>
<year>2020</year>;<volume>382</volume>:<fpage>929</fpage>-<lpage>36</lpage>.<pub-id pub-id-type="pmid">32004427</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal"><collab>European Medicine Agency</collab>.
Available at: <comment><ext-link ext-link-type="uri" xlink:href="ihttps://www.ema.europa.eu/en/documents/product-information/roactemraepar-product-information_it.pdf">ihttps://www.ema.europa.eu/en/documents/product-information/roactemraepar-product-information_it.pdf</ext-link></comment>
(Last Access 10th March 2020)</mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>RQ</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>FDA approval summary: tocilizumab for
treatment of chimeric antigen receptor T cell induced severe or life threatening
cytokine release syndrome</article-title>. <source>The Oncologist</source>
<year>2018</year>;<volume>23</volume>:<fpage>943</fpage>.<pub-id pub-id-type="pmid">29622697</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>On the use of corticosteroids for
2019-nCoV pneumonia</article-title>. <source>The Lancet</source>
<year>2020</year></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Clinical characteristics of 138
hospitalized patients with 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan,
China</article-title>. <source>JAMA</source>
<year>2020</year> Feb 7.</mixed-citation></ref><ref id="ref40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>
<article-title>Pathological findings of COVID-19
associated with acute respiratory distress syndrome</article-title>. <source>Lancet Resp
Med</source>
<year>2020</year>. doi.org/10.1016/S2213-2600(20)30076-X</mixed-citation></ref><ref id="ref41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiaoling</surname><given-names>X</given-names></name><name><surname>Mingfeng</surname><given-names>H</given-names></name><name><surname>Tiantian</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Effective Treatment of Severe COVID-19
Patients with Tocilizumab</article-title>. <year>2020</year>.
chinaXiv:202003.00026v1</mixed-citation></ref><ref id="ref42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riegler</surname><given-names>LL</given-names></name><name><surname>Jones</surname><given-names>GP</given-names></name><name><surname>Lee</surname><given-names>DW</given-names></name></person-group>
<article-title>Current approaches in the grading and management
of cytokine release syndrome after chimeric antigen receptor T-cell
therapy</article-title>. <source>Therapeut Clin Risk Manag</source>
<year>2019</year>; <volume>15</volume>:<fpage>323</fpage>.</mixed-citation></ref><ref id="ref43"><mixed-citation publication-type="journal"><collab>European Medicine Agency</collab>.
<article-title>Assessment Report. RoActemra</article-title>. <source>Procedure No.
EMEA/H/C/000955/II/0078</source>. 28 June <year>2018</year>.</mixed-citation></ref><ref id="ref44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbe</surname><given-names>CP</given-names></name><name><surname>Kruger</surname><given-names>M</given-names></name><name><surname>Rutherford</surname><given-names>P</given-names></name><name><surname>Gemmel</surname><given-names>L.</given-names></name></person-group>
<article-title>Validation of a modified Early Warning Score in medical
admissions</article-title>. <source>QJM</source>
<year>2001</year>;<volume>94</volume>:<fpage>521</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">11588210</pub-id></mixed-citation></ref></ref-list></back></article>